...
zntl-img

Zentalis Pharmaceuticals Llc, Common Stock

ZNTL

NASDAQ

$3.1

+$0.01

(0.32%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$220.21M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.73M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.74
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.66 L
$18.07 H
$3.1

About Zentalis Pharmaceuticals Llc, Common Stock

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameZNTLSectorS&P500
1-Week Return-20.31%-3.72%-0.05%
1-Month Return1.64%-1.85%2.75%
3-Month Return-15.76%-11.4%7.4%
6-Month Return-63.05%-4.41%10.47%
1-Year Return-77.67%4.13%27.57%
3-Year Return-95.95%0.3%29.56%
5-Year Return-86.64%36.62%89.3%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue111.00K160.00K544.00K1.43M1.39M[{"date":"2019-12-31","value":7.78,"profit":true},{"date":"2020-12-31","value":11.22,"profit":true},{"date":"2021-12-31","value":38.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.41,"profit":true}]
Gross Profit(111.00K)(160.00K)(544.00K)(1.43M)(1.39M)[{"date":"2019-12-31","value":-11100000,"profit":false},{"date":"2020-12-31","value":-16000000,"profit":false},{"date":"2021-12-31","value":-54400000,"profit":false},{"date":"2022-12-31","value":-142600000,"profit":false},{"date":"2023-12-31","value":-138900000,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses46.84M118.79M216.54M227.29M252.55M[{"date":"2019-12-31","value":18.55,"profit":true},{"date":"2020-12-31","value":47.03,"profit":true},{"date":"2021-12-31","value":85.74,"profit":true},{"date":"2022-12-31","value":90,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(46.84M)(118.79M)(216.54M)(227.29M)(248.99M)[{"date":"2019-12-31","value":-4684500000,"profit":false},{"date":"2020-12-31","value":-11878700000,"profit":false},{"date":"2021-12-31","value":-21654200000,"profit":false},{"date":"2022-12-31","value":-22728700000,"profit":false},{"date":"2023-12-31","value":-24898800000,"profit":false}]
Total Non-Operating Income/Expense980.00K----[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(46.36M)(118.10M)(164.56M)(221.30M)(276.89M)[{"date":"2019-12-31","value":-4636300000,"profit":false},{"date":"2020-12-31","value":-11810400000,"profit":false},{"date":"2021-12-31","value":-16455900000,"profit":false},{"date":"2022-12-31","value":-22130000000,"profit":false},{"date":"2023-12-31","value":-27689200000,"profit":false}]
Income Taxes15.00K444.00K(297.00K)(469.00K)(601.00K)[{"date":"2019-12-31","value":3.38,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-66.89,"profit":false},{"date":"2022-12-31","value":-105.63,"profit":false},{"date":"2023-12-31","value":-135.36,"profit":false}]
Income After Taxes(46.38M)----[{"date":"2019-12-31","value":-4637800000,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(46.38M)(118.55M)(164.26M)(220.83M)(286.35M)[{"date":"2019-12-31","value":-4637800000,"profit":false},{"date":"2020-12-31","value":-11854800000,"profit":false},{"date":"2021-12-31","value":-16426200000,"profit":false},{"date":"2022-12-31","value":-22083100000,"profit":false},{"date":"2023-12-31","value":-28635000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(46.38M)(118.55M)(164.26M)(220.83M)(292.19M)[{"date":"2019-12-31","value":-4637800000,"profit":false},{"date":"2020-12-31","value":-11854800000,"profit":false},{"date":"2021-12-31","value":-16426200000,"profit":false},{"date":"2022-12-31","value":-22083100000,"profit":false},{"date":"2023-12-31","value":-29219100000,"profit":false}]
EPS (Diluted)-(5.58)(4.94)(4.53)(4.64)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-558,"profit":false},{"date":"2021-12-31","value":-494,"profit":false},{"date":"2022-12-31","value":-453,"profit":false},{"date":"2023-12-31","value":-464,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ZNTL
Cash Ratio 7.13
Current Ratio 7.29

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ZNTL
ROA (LTM) -25.24%
ROE (LTM) -42.89%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ZNTL
Debt Ratio Lower is generally better. Negative is bad. 0.21
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.79

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ZNTL
Trailing PE NM
Forward PE NM
P/S (TTM) 5.43
P/B 0.62
Price/FCF NM
EV/R 7.77
EV/Ebitda NM

FAQs

What is Zentalis Pharmaceuticals Llc share price today?

Zentalis Pharmaceuticals Llc (ZNTL) share price today is $3.1

Can Indians buy Zentalis Pharmaceuticals Llc shares?

Yes, Indians can buy shares of Zentalis Pharmaceuticals Llc (ZNTL) on Vested. To buy Zentalis Pharmaceuticals Llc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ZNTL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Zentalis Pharmaceuticals Llc be purchased?

Yes, you can purchase fractional shares of Zentalis Pharmaceuticals Llc (ZNTL) via the Vested app. You can start investing in Zentalis Pharmaceuticals Llc (ZNTL) with a minimum investment of $1.

How to invest in Zentalis Pharmaceuticals Llc shares from India?

You can invest in shares of Zentalis Pharmaceuticals Llc (ZNTL) via Vested in three simple steps:

  • Click on Sign Up or Invest in ZNTL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Zentalis Pharmaceuticals Llc shares
What is Zentalis Pharmaceuticals Llc 52-week high and low stock price?

The 52-week high price of Zentalis Pharmaceuticals Llc (ZNTL) is $18.07. The 52-week low price of Zentalis Pharmaceuticals Llc (ZNTL) is $2.66.

What is Zentalis Pharmaceuticals Llc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Zentalis Pharmaceuticals Llc (ZNTL) is

What is Zentalis Pharmaceuticals Llc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Zentalis Pharmaceuticals Llc (ZNTL) is 0.62

What is Zentalis Pharmaceuticals Llc dividend yield?

The dividend yield of Zentalis Pharmaceuticals Llc (ZNTL) is 0.00%

What is the Market Cap of Zentalis Pharmaceuticals Llc?

The market capitalization of Zentalis Pharmaceuticals Llc (ZNTL) is $220.21M

What is Zentalis Pharmaceuticals Llc’s stock symbol?

The stock symbol (or ticker) of Zentalis Pharmaceuticals Llc is ZNTL

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top